Cartesian Therapeutics (RNAC) AI Stock Analysis

• Market Cap: $295.10M
• Dividend Yield: N/A
• Average Volume (3M): 68.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.98
• Revenue Growth: 38.82%
• EPS Growth: -645.78%
• Country: US
• Employees: 66
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.68
• Shares Outstanding: 25,954,290
• 10 Day Avg. Volume: 82,365
• 30 Day Avg. Volume: 68,613
• PEG Ratio: -0.02
• Price to Book (P/B): 1.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.98
• Enterprise Value/Market Cap: 0.32
• Enterprise Value/Revenue: 0.54
• Enterprise Value/Gross Profit: 2.80
• Enterprise Value/Ebitda: -0.15
• 1Y Price Target: $40.20
• Price Target Upside: 253.56% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 52 Neutral
• Price Target: $11.00 ▼(-3.25%Downside)

Cartesian Therapeutics' stock score is primarily hindered by its weak financial performance and valuation, reflecting significant financial instability and lack of profitability. However, promising Phase 2b trial results provide a positive outlook in the biotechnology sector, showcasing potential for future growth if successful. Technical indicators suggest neutral momentum without a clear trend direction.

Positive Factors

Efficacy Results

Descartes-08 has shown deep and durable efficacy with patients, supported by compelling Phase 2a and Phase 2b trial results.

Financial Position

Cartesian ended 1Q25 with $182.1M in cash and equivalents, which is sufficient to fund operations through completion of the Phase 3 AURORA trial and into mid-2027.

Trial Progress

The initiation of the Phase 3 AURORA trial for Descartes-08 in myasthenia gravis aligns with prior guidance, indicating strong adherence to planned timelines.

Negative Factors

Clinical Risks

Risks include delays in moving candidates through trials and failure to generate favorable clinical data, particularly with Descartes-08 in myasthenia gravis.

Data Dependence

There is anticipation for Phase 3 AURORA initiation and clinical execution and data updates across the broader AID pipeline, which could impact investor sentiment if expectations are not met.

Cartesian Therapeutics Business Overview & Revenue Model

Company Description

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

Cartesian Therapeutics makes money through the development and commercialization of its RNA-based cell therapies. Revenue streams include partnerships with pharmaceutical companies for co-development and licensing agreements, as well as potential future sales of approved therapeutic products. The company may also receive funding through research grants and collaborations with academic institutions. Additionally, strategic partnerships and investments provide financial support and contribute to its earnings.

Cartesian Therapeutics Financial Statement Overview

Summary

Cartesian Therapeutics shows severe financial distress, with a concerning income statement marked by high operational losses and declining revenues. The balance sheet is weak, evidenced by negative stockholders' equity, and the cash flow situation is poor with negative free cash flow. The company appears heavily reliant on external financing.

Income Statement

Cartesian Therapeutics shows a concerning trend in profitability, with a negative TTM net profit margin of -112.1% and a declining revenue trend. The gross profit margin remains high at 99.4% in the TTM, but the company struggles with negative EBIT and EBITDA margins, indicating operational inefficiencies and high costs relative to revenue.

Balance Sheet

The company's balance sheet is weak, highlighted by a negative stockholders' equity of -$21.79 million in the TTM, indicating financial distress. The debt-to-equity ratio cannot be calculated due to negative equity, and the equity ratio is also negative. These factors point to potential liquidity issues and high leverage risk, despite having substantial cash reserves.

Cash Flow

Cartesian Therapeutics has a negative free cash flow in the TTM of -$40.43 million, indicating cash outflow concerns. The operating cash flow to net income ratio shows operational cash drain, reflecting inefficiencies. However, significant financing cash flow suggests reliance on external funding to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	34.17M	38.91M	26.00M	110.78M	85.08M	16.60M
Gross Profit	33.98M	38.91M	24.45M	108.74M	85.08M	16.60M
EBITDA	-40.08M	-77.14M	-235.06M	39.84M	-5.16M	-65.59M
Net Income	-38.31M	-77.42M	-219.71M	35.38M	-25.69M	-68.88M
Balance Sheet
Total Assets	409.13M	435.02M	305.05M	165.89M	159.88M	165.44M
Cash, Cash Equivalents and Short-Term Investments	180.43M	212.61M	76.91M	134.60M	128.06M	138.69M
Total Debt	14.07M	13.98M	10.96M	37.92M	35.28M	35.35M
Total Liabilities	430.92M	441.82M	745.23M	72.06M	137.36M	183.44M
Stockholders Equity	-21.79M	-6.80M	-440.18M	93.83M	22.52M	-18.01M
Cash Flow
Free Cash Flow	-40.43M	-32.77M	-51.37M	-32.83M	-61.47M	34.07M
Operating Cash Flow	-30.86M	-23.67M	-51.16M	-31.63M	-60.38M	34.88M
Investing Cash Flow	-9.21M	-8.74M	34.61M	-15.00M	-17.14M	-741.00K
Financing Cash Flow	117.37M	168.43M	-13.14M	39.22M	52.90M	14.43M

Cartesian Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.37
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNAC, the sentiment is Positive. The current price of 11.37 is above the 20-day moving average (MA) of 10.41, above the 50-day MA of 10.53, and below the 200-day MA of 16.23, indicating a neutral trend. The MACD of 0.15 indicates Negative momentum. The RSI at 58.04 is Neutral, neither overbought nor oversold. The STOCH value of 62.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RNAC.

Cartesian Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARCT	53 Neutral	$352.30M	―	-27.40%	―	15.40%	35.42%
RNAC	52 Neutral	$295.10M	―	-938.38%	―	38.82%	-645.78%
VERV	52 Neutral	$1.01B	―	-34.26%	―	271.44%	26.65%
Sector *	51 Neutral	$7.50B	0.32	-61.87%	2.27%	17.10%	1.59%
ATYR	51 Neutral	$469.94M	―	-79.51%	―	-100.00%	10.73%
AURA	43 Neutral	$400.55M	―	-56.24%	―	―	9.22%
ORKA	41 Neutral	$472.12M	―	-39.06%	―	―	-48.01%

Cartesian Therapeutics Corporate Events

Cartesian Therapeutics Holds Annual Stockholders Meeting

On June 13, 2025, Cartesian Therapeutics, Inc. held its Annual Meeting of Stockholders, where 21,868,804 shares were represented, accounting for approximately 84.31% of the company’s outstanding stock. During the meeting, three Class III Directors were elected to serve until the 2028 Annual Meeting, the compensation of the company’s named executive officers was approved on a non-binding basis, and Ernst & Young LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2025.

The most recent analyst rating on (RNAC) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Cartesian Therapeutics stock, see the RNAC Stock Forecast page.

Cartesian Therapeutics CTO Transition to Consultant Role

On April 29, 2025, Cartesian Therapeutics, Inc. announced that its Chief Technology Officer, Metin Kurtoglu, will end his employment with the company on May 1, 2025. Following this, he will transition to a consulting role from May 1, 2025, to April 30, 2026. The agreements include a separation deal where Dr. Kurtoglu will release any claims against the company in exchange for severance benefits, including 12 months’ salary, a pro-rated bonus, and accelerated vesting of equity awards.

Cartesian Therapeutics Unveils Promising Phase 2b Trial Results

On April 8, 2025, Cartesian Therapeutics announced 12-month efficacy and safety data from its Phase 2b trial of Descartes-08 for generalized myasthenia gravis (MG). The trial demonstrated sustained symptom improvement and a favorable safety profile, supporting outpatient administration. Notably, participants without prior biologic therapies showed the most compelling responses, with significant reductions in MG-ADL scores. The results reinforce Descartes-08’s potential to transform MG treatment, and the company plans to commence a Phase 3 trial in the second quarter of 2025.